EMEA-000716-PIP01-09-M05 - paediatric investigation plan

siponimod (hemifumarate)

Key facts

• Invented name:
  Mayzent
• Active substance:
  siponimod (hemifumarate)
• Therapeutic area:
  Neurology
• Decision number:
  P/0531/2022
• PIP number:
  EMEA-000716-PIP01-09-M05
• Pharmaceutical form(s):
  Film-coated tablet
• Condition(s) / indication(s):
  Treatment of multiple sclerosis
• Route(s) of administration:
  Oral use
• Decision type:
  PM: decision on the application for modification of an agreed PIP
• Decision date:
  30/12/2022
• Compliance check done:
  No

Decision

P/0531/2022: EMA decision of 30 December 2022 on the acceptance of a modification of an agreed paediatric investigation plan for siponimod (hemifumarate) (Mayzent), (EMEA-000716-PIP01-09-M05)

Adopted Reference Number: EMA/929763/2022